This time, I'd like to talk about vaccinations for cervical cancer.
I'm talking about vaccination systems, and how people view vaccinations in different ways.Even if it is statistically considered beneficial, it may not be one of those numbers.
Some people see it as
Or we can do what we can to reduce the risk as much as possible. In other cases, we can do what we can to reduce the risk.
This time, I'd like to introduce a study on vaccination against cervical cancer caused by HPV. This time, I'd like to introduce you to a study on HPV vaccination.
What are the studies?
26 studies (73,428 participants) were included.
Protection against CIN / AIS was addressed in 10 trials with follow-up of 1.3 to 8 years.Vaccine safety was assessed in 23 studies over a period of 6 months to 7 years.The studies are not large enough or of sufficient duration to assess cervical cancer outcomes.All but one trial was funded by the vaccine manufacturer.
Most of the included trials were judged to have a low risk of bias.
The studies included monovalent (n = 1), bivalent (n = 18), and quadrivalent vaccines (n = 7). Most women were under 26 years of age; three trials recruited women over 25 years of age. Vaccine efficacy in participants who received at least one dose of vaccination is summarized.
Results.
There is solid evidence that the HPV vaccine prevents cervical precancer in adolescent girls and young women between the ages of 15 and 26.Regardless of the type of HPV, the effect is higher for lesions associated with HPV16 / 18.Those who are negative for hrHPV or HPV16 / 18 DNA at the time of enrollment will have a greater effect than those whose HPV DNA status is not selected.There is evidence of moderate certainty that the HPV vaccine reduces CIN2+ in older women who are HPV16/18 negative, but not in those who are unselected for HPV DNA status.
There was no increased risk of serious adverse effects.
Although the overall number of deaths was small, there were more deaths among women over 25 years of age who received the vaccine.It has been determined that the deaths reported in this study were not related to the vaccine.An increased risk of adverse pregnancy outcomes after HPV vaccination cannot be ruled out, but the risk of miscarriage and termination is similar between the study groups.Long-term follow-up is needed to monitor the effects on cervical cancer, the occurrence of rare harms, and pregnancy outcomes.
Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Vaccination against human papillomavirus to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2018, Issue 5. Issue 5. art. no.: CD009069. doi: 10.1002 / 14651858.CD009069.pub
Conclusion
The results show that beneficial effects can be expected, and the number of adverse reports and other incidences are considered to be rare, and deaths are not associated.The study included people from Europe, Asia Pacific, and North and South America, so the results are applicable to Japanese as well.
However, the researchers commented that the results of this study will be updated over the years as adverse cases are reported.Although vaccination is not considered to be a major problem, some serious cases have been reported.
